Brian Kennedy, PhD, CEO & President

Brian K. Kennedy, Ph.D., has an international reputation for his work in the basic biology of aging. He became the Buck Institute’s second CEO in July, 2010, coming from the University of Washington in Seattle where he served in the Department of Biochemistry. 

Kennedy earned his Ph.D. from the Massachusetts Institute of Technology.  He is well known for work during his graduate studies with Leonard Guarente PhD, which led to the discovery that Sirtuins (SIR2) modulate aging. His current work involves nutrient signaling pathways linked to dietary restriction, particularly the TOR pathway.  He also studies A-type nuclear lamins, which are targets for mutation in Hutchinson-Gilford progeria syndrome.  

A native of Louisville, Kentucky, Dr. Kennedy has served on the National Institutes of Health Cellular Mechanisms of Aging and Development study section since 2006, and on the grant review committee for American Federation for Aging Research Grants since 2006. He has published more than 60 manuscripts in prestigious journals including Cell, Nature, Science, and the Proceedings of the National Academy of Sciences. He has been an Associate Editor for the Journal of Gerontology since 2006, and also serves as a consultant for biotech and pharmaceutical companies.

Brian K. Kennedy, CEO
brian.kennedy@buckinstitute.org

Share:
Change text size:
smaller

default

bigger